All‐cause mortality · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D may leads to lower all‐cause mortality compared with placebo or no intervention (low certainty).
1 finding from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).
1 finding from 1 review
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in all‐cause mortality (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
All‐cause mortality · people with chronic liver diseases
It is very uncertain whether vitamin D changes all‐cause mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · children under 5 years of age
1 finding from 1 review
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · children aged between 6 months and 5 years
Vitamin A supplementation leads to lower all‐cause mortality compared with placebo or usual care (high certainty).
1 finding from 1 review
All‐cause mortality · general population over 2 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · general population over 2 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · general population over 2 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality Physicians · middle‐aged US male physicians
It is very uncertain whether vitamin C supplementation changes all‐cause mortality Physicians compared with placebo (very low certainty).
1 finding from 1 review
Death at hospital discharge · individuals with moderate to severe disease
1 finding from 1 review
Neonatal mortality · mortality and morbidity in term neonates
Neonatal vitamin A supplementation showed no clear difference in all‐cause neonatal mortality: risk ratios based on cumulative risk… compared with control (high certainty).
1 finding from 1 review
Infant Mortality at 6 Months · mortality and morbidity in term neonates
Neonatal vitamin A supplementation showed no clear difference in all‐cause infant mortality at 6 months: risk ratios based on… compared with control (high certainty).
1 finding from 1 review
All‐cause infant mortality at 6 months: risk ratios based on cumulative risk (%, adjusted for clustering) ‐ term infants · mortality and morbidity in term neonates
It is very uncertain whether neonatal vitamin A supplementation changes all‐cause infant mortality at 6 months: risk ratios based on… compared with control (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality in trials using vitamin D3 (cholecalciferol) ( · adults
The intervention probably leads to lower all‐cause mortality in trials using vitamin D3 (cholecalciferol) ( (moderate certainty).
1 finding from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).
2 findings from 1 review
All‐cause mortality · people with cancer with VTE receiving secondary prophylaxis
Idraparinux secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
1 finding from 1 review